Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Relapsed Multiple Myeloma - Pipeline Review, H2 2013 - New Study Released


Print article Print article
2013-10-03 14:31:43 - Recently published research from Global Markets Direct, "Relapsed Multiple Myeloma - Pipeline Review, H2 2013", is now available at Fast Market Research

Global Markets Direct's, 'Relapsed Multiple Myeloma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Relapsed Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma. Relapsed Multiple Myeloma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of

data for the indicated disease.

Full Report Details at
- www.fastmr.com/prod/689108_relapsed_multiple_myeloma_pipeline_re ..

Scope

* A snapshot of the global therapeutic scenario for Relapsed Multiple Myeloma.
* A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Relapsed Multiple Myeloma pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., Genentech, Inc., Piramal Healthcare Limited, Prolexys Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Astellas Pharma Inc., ImmunoGen, Inc., Exelixis, Inc., Onyx Pharmaceuticals, Inc., Incyte Corporation, AEterna Zentaris Inc., Pharmacyclics, Inc., Array BioPharma Inc., MorphoSys AG, Senesco Technologies, Inc., Synta Pharmaceuticals Corp., Acceleron Pharma, Inc., Altor BioScience Corporation, Stemline Therapeutics, Inc., Acetylon Pharmaceuticals, Inc., PharmaMar, S.A., Cylene Pharmaceuticals, Inc., Centocor Ortho Biotech, Inc.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Relapsed Multiple Myeloma Overview
Therapeutics Development
An Overview of Pipeline Products for Relapsed Multiple Myeloma
Relapsed Multiple Myeloma Therapeutics under Development by Companies
Relapsed Multiple Myeloma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Relapsed Multiple Myeloma Therapeutics - Products under Development by Companies
Relapsed Multiple Myeloma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Relapsed Multiple Myeloma Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Kyowa Hakko Kirin Co., Ltd.
Genentech, Inc.
Piramal Healthcare Limited
Prolexys Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
ImmunoGen, Inc.
Exelixis, Inc.
Onyx Pharmaceuticals, Inc.
Incyte Corporation
AEterna Zentaris Inc.
Pharmacyclics, Inc.
Array BioPharma Inc.
MorphoSys AG
Senesco Technologies, Inc.
Synta Pharmaceuticals Corp.
Acceleron Pharma, Inc.
Altor BioScience Corporation
Stemline Therapeutics, Inc.
Acetylon Pharmaceuticals, Inc.
PharmaMar, S.A.
Cylene Pharmaceuticals, Inc.
Centocor Ortho Biotech, Inc.
Relapsed Multiple Myeloma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
perifosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bendamustine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lorvotuzumab mertansine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-833923 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=689108&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser